A new risk score model for hepatocellular carcinoma using standard clinical data can better identify individuals at risk better than the current standard risk models.

AI models can be useful tools for clinicians, helping assess risk in patients with HCC to inform disease management. | Image credit: ipopba - stock.adobe.com

AI Model Precisely Identifies HCC Recurrence Risk Factors

By Rose McNulty

July 26th 2024

Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found.

Illustration of liver cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com

Response to Immunotherapy Linked With Improved Liver Function in Advanced HCC

By Rose McNulty

July 22nd 2024

Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.

Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center

Dr Amit Singal on Unmet Needs in HCC, Shifts in At-Risk Populations

By Rose McNulty

July 10th 2024

While there have been advances in screening technology, it is crucial to continue investing in emerging modalities and to ensure these advancements translate to clinical practice.

A retrospective study aimed to determine whether adding PD-1 inhibitors to TACE plus lenvatinib improved the prognosis of patients with unresectable hepatocellular carcinoma. | Image credit: Crystal light - stock.adobe.com

Study: Adding Anti–PD-1 to TACE Plus Lenvatinib Does Not Improve PFS in Unresectable HCC

By Rose McNulty

July 3rd 2024

The addition of PD-1 inhibitors to first-line treatment with transarterial chemoembolization (TACE) plus lenvatinib for hepatocellular carcinoma (HCC).

<1 2

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions